October 7, 2024
Abstract Objectives: To determine baseline prevalence of proteinuria and albuminuria among REPRIEVE participants and evaluate associated risk factors. Design: Cross sectional analysis of a baseline sample of participants […]
September 11, 2024
Cardiovascular disease (CVD) rates are increased 50%-100% among people with HIV. The mechanisms of CVD in people with HIV include traditional risk factors such as smoking, […]
September 4, 2024
By John W. McEvoy and Cian Mangan The potential of high-sensitivity cardiac troponin (hs-cTn) assays to augment cardiovascular disease (CVD) prediction in primary prevention has long been an […]
August 28, 2024
Abstract Background: Little is known about the potential benefits or harms of statins on physical function among people with HIV (PWH). Methods: REPRIEVE was a double-blind randomized controlled […]
August 28, 2024
Abstract Background Coronary plaque is common among people with HIV (PWH) with low-to-moderate traditional atherosclerotic cardiovascular disease (ASCVD) risk. Objectives The purpose of this study was […]
July 29, 2024
People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of […]
July 29, 2024
Current or previous use of the antiretroviral drug (ARV) abacavir was associated with an elevated risk of major adverse cardiovascular events (MACE) in people with HIV, […]
July 29, 2024
ACTG, a global clinical trials network focused on HIV and other infectious diseases, will present an exploratory analysis from the REPRIEVE trial demonstrating that former and […]
July 9, 2024
By Alicia Banks, Duke Global Health Institute As Gerald S. Bloomfield, M.D., saw heart patients in Kenya over the past decade, he knew that cardiovascular disease […]
October 7, 2024
Abstract Objectives: To determine baseline prevalence of proteinuria and albuminuria among REPRIEVE participants and evaluate associated risk factors. Design: Cross sectional analysis of a baseline sample of participants […]
September 11, 2024
Cardiovascular disease (CVD) rates are increased 50%-100% among people with HIV. The mechanisms of CVD in people with HIV include traditional risk factors such as smoking, […]
September 4, 2024
By John W. McEvoy and Cian Mangan The potential of high-sensitivity cardiac troponin (hs-cTn) assays to augment cardiovascular disease (CVD) prediction in primary prevention has long been an […]
August 28, 2024
Abstract Background: Little is known about the potential benefits or harms of statins on physical function among people with HIV (PWH). Methods: REPRIEVE was a double-blind randomized controlled […]
August 28, 2024
Abstract Background Coronary plaque is common among people with HIV (PWH) with low-to-moderate traditional atherosclerotic cardiovascular disease (ASCVD) risk. Objectives The purpose of this study was […]
July 29, 2024
People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of […]
July 29, 2024
Current or previous use of the antiretroviral drug (ARV) abacavir was associated with an elevated risk of major adverse cardiovascular events (MACE) in people with HIV, […]
July 29, 2024
ACTG, a global clinical trials network focused on HIV and other infectious diseases, will present an exploratory analysis from the REPRIEVE trial demonstrating that former and […]
July 9, 2024
By Alicia Banks, Duke Global Health Institute As Gerald S. Bloomfield, M.D., saw heart patients in Kenya over the past decade, he knew that cardiovascular disease […]